JP2003522148A - アルファ−２ｂ−アドレナリン受容体を媒介する疾患の処置又は予防に有用な化合物 - Google Patents
アルファ−２ｂ−アドレナリン受容体を媒介する疾患の処置又は予防に有用な化合物Info
- Publication number
- JP2003522148A JP2003522148A JP2001557564A JP2001557564A JP2003522148A JP 2003522148 A JP2003522148 A JP 2003522148A JP 2001557564 A JP2001557564 A JP 2001557564A JP 2001557564 A JP2001557564 A JP 2001557564A JP 2003522148 A JP2003522148 A JP 2003522148A
- Authority
- JP
- Japan
- Prior art keywords
- alpha
- adrenergic receptor
- disease
- selective
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title claims abstract description 48
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 title claims abstract description 25
- 201000010099 disease Diseases 0.000 title claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 16
- 230000001404 mediated effect Effects 0.000 title claims abstract description 8
- 239000000674 adrenergic antagonist Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 16
- 241000124008 Mammalia Species 0.000 claims abstract description 13
- 239000005557 antagonist Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 4
- 102100036666 Alpha-2B adrenergic receptor Human genes 0.000 claims description 13
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 11
- 208000029078 coronary artery disease Diseases 0.000 claims description 11
- 206010047139 Vasoconstriction Diseases 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 230000025033 vasoconstriction Effects 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 239000000048 adrenergic agonist Substances 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 102000008841 Alpha 2B adrenoceptor Human genes 0.000 claims description 3
- 108050000738 Alpha 2B adrenoceptor Proteins 0.000 claims description 3
- 206010002388 Angina unstable Diseases 0.000 claims description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
- 208000007530 Essential hypertension Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 201000001068 Prinzmetal angina Diseases 0.000 claims description 3
- 208000003782 Raynaud disease Diseases 0.000 claims description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 3
- 206010057040 Temperature intolerance Diseases 0.000 claims description 3
- 208000007814 Unstable Angina Diseases 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 3
- 238000007887 coronary angioplasty Methods 0.000 claims description 3
- 230000006806 disease prevention Effects 0.000 claims description 3
- 150000002306 glutamic acid derivatives Chemical class 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 201000011461 pre-eclampsia Diseases 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims 4
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 230000006931 brain damage Effects 0.000 claims 2
- 231100000874 brain damage Toxicity 0.000 claims 2
- 230000007012 clinical effect Effects 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 101710175728 Alpha-2B adrenergic receptor Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 229940082496 Adrenoreceptor antagonist Drugs 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 108060003345 Adrenergic Receptor Proteins 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 229960001289 prazosin Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008345 muscle blood flow Effects 0.000 description 2
- 210000000478 neocortex Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 238000003345 scintillation counting Methods 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- OGIYDFVHFQEFKQ-UHFFFAOYSA-N 3-[n-(4,5-dihydro-1h-imidazol-2-ylmethyl)-4-methylanilino]phenol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 OGIYDFVHFQEFKQ-UHFFFAOYSA-N 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- BLGXFZZNTVWLAY-DIRVCLHFSA-N rauwolscine Chemical compound C1=CC=C2C(CCN3C[C@H]4CC[C@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-DIRVCLHFSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18202100P | 2000-02-11 | 2000-02-11 | |
| US60/182,021 | 2000-02-11 | ||
| FI20000303 | 2000-02-14 | ||
| FI20000303A FI20000303A0 (fi) | 2000-02-14 | 2000-02-14 | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet |
| PCT/FI2001/000105 WO2001058454A1 (en) | 2000-02-11 | 2001-02-07 | Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2003522148A true JP2003522148A (ja) | 2003-07-22 |
Family
ID=26160944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001557564A Pending JP2003522148A (ja) | 2000-02-11 | 2001-02-07 | アルファ−２ｂ−アドレナリン受容体を媒介する疾患の処置又は予防に有用な化合物 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1253926A1 (ru) |
| JP (1) | JP2003522148A (ru) |
| KR (1) | KR20020080413A (ru) |
| AU (1) | AU780802B2 (ru) |
| BR (1) | BR0108221A (ru) |
| CA (1) | CA2399421A1 (ru) |
| CZ (1) | CZ20022884A3 (ru) |
| EA (1) | EA200200846A1 (ru) |
| EE (1) | EE200200435A (ru) |
| GE (1) | GEP20043356B (ru) |
| HR (1) | HRP20020746A2 (ru) |
| HU (1) | HUP0300032A3 (ru) |
| IL (1) | IL151017A0 (ru) |
| IS (1) | IS6476A (ru) |
| MX (1) | MXPA02007454A (ru) |
| MY (1) | MY133957A (ru) |
| NO (1) | NO20023773D0 (ru) |
| NZ (1) | NZ520500A (ru) |
| PL (1) | PL357872A1 (ru) |
| SK (1) | SK11472002A3 (ru) |
| WO (1) | WO2001058454A1 (ru) |
| YU (1) | YU59102A (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI116940B (fi) | 2001-07-20 | 2006-04-13 | Juvantia Pharma Ltd Oy | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet |
| NZ530366A (en) * | 2001-07-20 | 2005-02-25 | Juvantia Pharma Ltd Oy | Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8416432D0 (en) * | 1984-06-28 | 1984-08-01 | Wyeth John & Brother Ltd | Benzoquinolizines |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| US6150389A (en) * | 1994-07-11 | 2000-11-21 | Allergan Sales, Inc. | Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents |
-
2001
- 2001-02-07 NZ NZ520500A patent/NZ520500A/en unknown
- 2001-02-07 HU HU0300032A patent/HUP0300032A3/hu unknown
- 2001-02-07 MX MXPA02007454A patent/MXPA02007454A/es unknown
- 2001-02-07 SK SK1147-2002A patent/SK11472002A3/sk unknown
- 2001-02-07 YU YU59102A patent/YU59102A/sh unknown
- 2001-02-07 EE EEP200200435A patent/EE200200435A/xx unknown
- 2001-02-07 GE GE4893A patent/GEP20043356B/en unknown
- 2001-02-07 PL PL01357872A patent/PL357872A1/xx not_active Application Discontinuation
- 2001-02-07 KR KR1020027010329A patent/KR20020080413A/ko not_active Application Discontinuation
- 2001-02-07 EP EP01907585A patent/EP1253926A1/en not_active Withdrawn
- 2001-02-07 CZ CZ20022884A patent/CZ20022884A3/cs unknown
- 2001-02-07 BR BR0108221-3A patent/BR0108221A/pt not_active IP Right Cessation
- 2001-02-07 IL IL15101701A patent/IL151017A0/xx unknown
- 2001-02-07 EA EA200200846A patent/EA200200846A1/ru unknown
- 2001-02-07 JP JP2001557564A patent/JP2003522148A/ja active Pending
- 2001-02-07 WO PCT/FI2001/000105 patent/WO2001058454A1/en not_active Application Discontinuation
- 2001-02-07 AU AU35510/01A patent/AU780802B2/en not_active Ceased
- 2001-02-07 CA CA002399421A patent/CA2399421A1/en not_active Abandoned
- 2001-02-09 MY MYPI20010579A patent/MY133957A/en unknown
-
2002
- 2002-07-19 IS IS6476A patent/IS6476A/is unknown
- 2002-08-09 NO NO20023773A patent/NO20023773D0/no not_active Application Discontinuation
- 2002-09-11 HR HRP20020746 patent/HRP20020746A2/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2399421A1 (en) | 2001-08-16 |
| SK11472002A3 (sk) | 2003-02-04 |
| HRP20020746A2 (en) | 2004-12-31 |
| GEP20043356B (en) | 2004-04-13 |
| HUP0300032A2 (en) | 2003-05-28 |
| EP1253926A1 (en) | 2002-11-06 |
| HUP0300032A3 (en) | 2006-01-30 |
| IL151017A0 (en) | 2003-02-12 |
| EA200200846A1 (ru) | 2002-12-26 |
| AU3551001A (en) | 2001-08-20 |
| YU59102A (sh) | 2005-11-28 |
| IS6476A (is) | 2002-07-19 |
| EE200200435A (et) | 2003-12-15 |
| NO20023773L (no) | 2002-08-09 |
| AU780802B2 (en) | 2005-04-21 |
| MY133957A (en) | 2007-11-30 |
| BR0108221A (pt) | 2003-03-05 |
| NZ520500A (en) | 2005-01-28 |
| KR20020080413A (ko) | 2002-10-23 |
| WO2001058454A1 (en) | 2001-08-16 |
| MXPA02007454A (es) | 2004-08-23 |
| PL357872A1 (en) | 2004-07-26 |
| CZ20022884A3 (cs) | 2003-02-12 |
| NO20023773D0 (no) | 2002-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Traish et al. | Role of alpha adrenergic receptors in erectile function | |
| JP6087836B2 (ja) | 併用療法 | |
| JP2010514696A (ja) | 心血管症状の低減 | |
| JP2002502370A (ja) | 脳血管障害の処置に有用な薬剤の調製のための１，２，４−トリアゾロ［１，５−ｃ］ピリミジン複素環アナログの使用 | |
| Mizobe et al. | α2-Adrenoceptor agonists and anesthesia | |
| US20100256187A1 (en) | Composition of 2,4,6- trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide | |
| JP2002526408A (ja) | 疼痛および不安の処置のためのｍｇｌｕｒ５アンタゴニスト | |
| Pupo et al. | Adrenergic pharmacology: focus on the central nervous system | |
| US20020002142A1 (en) | Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation | |
| JP4380800B2 (ja) | マラリアの処置のための（＋）メフロキンの使用 | |
| IL167849A (en) | Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration | |
| TW445147B (en) | Pharmaceutical composition for preventing and treating postischemic renal failure and for protecting the ischemic kidney, comprising an AT1-receptor antagonist | |
| Blasdel et al. | Therapeutic drug monitoring in CML patients on imatinib | |
| JP2003522148A (ja) | アルファ−２ｂ−アドレナリン受容体を媒介する疾患の処置又は予防に有用な化合物 | |
| US6521632B2 (en) | Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor | |
| TW202140015A (zh) | 用於治療癌症之表皮生長因子受體酪胺酸激酶抑制劑 | |
| Ogata et al. | Sympatholytic agents | |
| US4520024A (en) | Method of selectively blocking peripheral vascular serotonergic receptors | |
| JP5881671B2 (ja) | チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 | |
| Sung et al. | I007: Differences in dose-response pattern of angiotensin II on blood pressure and venoconstriction in humans | |
| Kim et al. | Bradycardia Induced by Mivazerol, a Selective α 2-Adrenoceptor Agonist, Is Amplified During Mild Hypothermia in the Pentobarbital-Anesthetized Rat | |
| Söhren et al. | Benjamin Kloth, Simon Pecha, Eileen Moritz3, Yvonne Schneeberger |